We demonstrate that the VEGF receptor, neuropilin-2 (NRP2) is associated with high-grade, PTEN-null prostate cancer and that its expression in tumor cells is induced by PTEN loss as a consequence of c-Jun activation. VEGF/NRP2 signaling represses IGF-1R expression and signaling and the mechanism involves Bmi-1-mediated transcriptional repression of the IGF-1R.
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INTRODUCTION
Understanding mechanisms that drive the initiation and progression of prostate cancer is essential to improving the clinical management of this disease, which is the most common cancer in men in the United States and Western Europe (1). Although early stage prostate cancer can be treated reasonably well clinically, advanced forms of this disease are very aggressive and difficult to manage with existing therapies. As a consequence, these tumors are associated with a high degree of morbidity and mortality. Our approach to understanding the biology of aggressive prostate cancer is rooted in the hypothesis that tumor cells express receptors for VEGF and that VEGF signaling in tumor cells contributes to tumor formation and progression (2) (3) (4) (5) . Surprisingly, however, little is known about the expression and function of VEGF receptors on prostate carcinoma cells and their contribution to this disease. This problem is significant because these receptors and the signaling pathways that they regulate are prime targets for therapeutic intervention.
The neuropilins (NRPs) are one class of VEGF receptors that are particularly interesting with respect to cancer biology. NRP1 and NRP2 were identified initially as neuronal receptors for semaphorins, which are axon guidance factors that function primarily in the developing nervous system (6, 7). The seminal finding by Klagsbrun that neuropilins can also function as VEGF receptors and that they are expressed on endothelial and tumor cells launched studies aimed at understanding their functional contribution to angiogenesis and tumor biology (8).
NRPs have the ability to interact with and modulate the function of tyrosine kinase VEGF receptors (VEGFR1 and VEGFR2), as well as other receptors (9, 10). There is also evidence that NRPs can function independently of other receptors (11) and that they are valid targets for therapeutic inhibition of angiogenesis and cancer (12) (13) (14) .
This study demonstrates that the expression of NRP2 in prostate cancer cells is induced by PTEN deletion and that its expression correlates with Gleason grade. Given that the inactivation of PTEN is one of the most common genetic lesions in prostate cancer and its Ͷ frequency increases with more aggressive disease (15), our discovery led to the hypothesis that VEGF/NRP2 signaling in tumor cells has a key role in prostate carcinogenesis. Indeed, the data obtained reveal that VEGF/NRP2 signaling contributes to the expression of Bmi-1, a Polycomb group transcriptional repressor that has been implicated in the etiology of prostate cancer induced by PTEN deletion (16). We also discovered that Bmi-1 represses transcription of the IGF-1 receptor (IGF-1R), which is relevant because IGF-1R signaling contributes to tumor growth (17) and the IGF-1R is a potential therapeutic target for prostate cancer (18). We conclude from our data that aggressive prostate cancer cells exhibit VEGF/NRP2 signaling, Bmi-1 expression and reduced IGF-1R expression. The functional and therapeutic implications of these findings were evaluated, and the results highlight a novel role for NRP2 as a biomarker for predicting response to IGF-1R therapy and as a therapeutic target itself in combination with expressed PTEN were negative for NRP2 ( Fig. 2A ). These data are consistent with the finding that PTEN loss occurs in approximately 15-20% of low-grade prostate cancer (15, 25) . The association between PTEN loss and NRP2 expression was substantiated by analyzing prostate tumors in PTEN pc-/-mice, which are invasive and aggressive (26). These tumors display relatively high NRP2 expression compared to the mouse prostatic epithelium (Fig. 2B ). NRP2
expression is also high in PIN lesions in the PTEN pc-/-mice consistent with the hypothesis that PTEN loss induces NRP2 (Fig. 2B ). This consequence of PTEN loss is specific to NRP2 because NRP1 is expressed in both normal prostate epithelium and PTEN pc-/-tumors (Fig. 2B , Supplementary Fig. 3A ). These results imply that PTEN represses NRP2 but not NRP1
expression. To test this hypothesis, PTEN was expressed in PC3 and C4-2 cells, which are PTEN-null and express NRP2. PTEN expression ablated NRP2 expression and the activity of a NRP2 promoter reporter construct but it had no effect on NRP1 expression ( Fig. 2C-E ). These results indicate that NRP2 is associated with aggressive, PTEN-null prostate cancer.
Importantly, NRP2 expression is not a function of tumor differentiation because of the heterogeneity of its expression in Grade 3 tumors, which are all differentiated, and our observation that NRP2 is not expressed in VCaP cells, which are poorly differentiated but PTEN-positive (Fig. 2D ). DU145 cells, which are PTEN-positive, also lack NRP2 (Fig. 2D ).
Additional evidence to support the conclusion that PTEN loss or inactivation induces NRP2 was obtained by evaluating AKT activation because it is a read-out of PTEN deletion and mutation (27) . Indeed, a significant correlation between p-AKT and NRP2 expression was observed in prostate tumors ( Supplementary Fig. 3B-C) .
To investigate the mechanism behind PTEN-mediated NRP2 suppression, we analyzed the role of c-Jun because it is activated upon PTEN deletion in prostate tumors and contributes to tumorigenesis (28, 29) . A significant down-regulation of c-Jun occurred upon PTEN expression in PC3 and C4-2 cells ( Fig. 2E-F) , and PTEN expression inhibited the activity of a cJun promoter and AP1 reporter constructs significantly (Fig. 2G) did not affect Coup-TFII, a transcription factor previously shown to regulate NRP2 in lymphatic vessel development (30) (Fig. 2F) . We established the role of c-Jun in the regulation of NRP2 using c-Jun shRNAs and TAM67 (a dominant negative c-Jun). Expression of either c-Jun shRNAs or TAM67 reduced NRP2 protein and mRNA levels, as well as NRP2 promoter activity (Fig. 3A-B) . Also, an increase in NRP2 promoter activity upon c-Jun over-expression was observed in PC3 and C4-2 cells (Fig. 3C) . These results indicate that PTEN represses NRP2 expression by inhibiting c-Jun. We assessed this hypothesis by demonstrating that c-Jun expression rescued NRP2 expression in PC3 and C4-2 cells that had been transfected with a PTEN construct (Fig. 3D) . Moreover, our analysis of recently published gene expression data derived from PTEN induction in Pten í/í cells (29) revealed an inverse correlation between c-Jun and PTEN, and NRP2 and PTEN expression (Fig. 3E ).
To investigate the regulation of NRP2 by c-Jun more rigorously, we performed ChIP and observed that c-Jun binds directly to distinct sites in the NRP2 promoter ( Fig. 3F-G ). More specifically, the NRP2 promoter contains two AP1 binding sites located within NP3 and NP7
( Fig. 3F ) and ChIP confirmed binding to these sites (Fig. 3G ). In addition, mutating these sites inhibited NRP2 promoter activity ( Supplementary Fig. 4A ). As further proof that PTEN represses NRP2 expression by a c-Jun-dependent mechanism, we observed that PTEN significantly inhibited the binding of c-Jun to the NRP2 promoter (Fig. 3H ). Given that JNKs are the upstream kinases that regulate c-Jun activity (31), we found that either a dominant-negative JNK or a JNK1 shRNA, but not a JNK2 shRNA inhibited NRP2 expression (Supplementary Fig.   4B -D).
NRP2 represses IGF-1R expression and inhibits IGF-1R signaling
To evaluate the role of NRP2 in prostate tumorigenesis, we generated PC3 cells with diminished NRP2 expression using shRNAs. Loss of NRP2 had no effect on morphology or proliferation on tissue culture plates (data not shown), but it did reduce the ability of these cells
Research. (Fig. 4A, left) . The NRP2-depleted cells also grew more slowly compared to control cells when implanted subcutaneously in mice (Fig. 4A, right) . Although significant, the impact of NRP2 loss on growth in soft agar and tumor formation in vivo was modest suggesting a potential compensatory mechanism. In this context, we observed a marked increase in IGF-1R mRNA expression concomitant with NRP2 loss but no change in the expression of either EGFR or insulin receptor mRNA expression (Fig. 4B ). This effect of NRP2 loss on the induction of IGF-1R expression was also evident at the protein level in both PC3 and C4-2 cells (Fig. 4C ).
This effect is specific to NRP2 because no change in IGF-1R expression was observed upon NRP1 loss (Fig. 4D) .
The repression of IGF-1R expression by NRP2 in PC3 cells was maintained in vivo as evidenced by the observation that loss of NRP2 induced a significant increase in IGF-1R in three independent xenograft tumors ( ( Supplementary Fig. 5A-C) . Thus, the mechanism we propose appears to be distinct from this interesting study because inactivation of FOXO factors affected a number of receptors including the insulin receptor, EGFR and c-met. In contrast, NRP2 represses only the IGF-1R (Fig. 4B ).
To investigate the role of NRP2 on IGF-1R signaling and function further, we expressed NRP2 in non-cancerous prostate epithelial cells p69, which express high levels of IGF-1R and less c-Jun compared to more aggressive cell lines (33). p69 cells are NRP2-null and expression of NRP2 reduced IGF-1R levels (Fig. 4F ). These cells also express endogenous VEGF ( Supplementary Fig. 5D ). Consistent with reduced IGF-1R expression, NRP2 expression (Fig. 4G, left) and IRS-1 phosphorylation (a substrate of IGF-1R tyrosine kinase) (Fig. 4G, right) . Based on these results, it is expected that PTEN positive tumors, which express low levels of NRP2, have high IGF-1R levels. This hypothesis was confirmed by analyzing gene expression derived from human prostate cancer specimens (n=128) (34). We found a positive correlation between IGF-1R and PTEN expression (p=2x10 -5 ) (Fig. 4H ).
The compensatory relationship between NRP2 and IGF-1R expression indicated that inhibition of both receptors would be more effective at impeding tumor growth than inhibition of either receptor individually. To test this hypothesis, we investigated the effect of an IGF-1R inhibitory antibody on the ability of control PC3 cells or cells in which NRP2 expression had been ablated to grow in soft agar or in immunocompromised mice. A significant effect of combined NRP2 down-regulation and IGF-1R inhibition was evident in both soft agar growth in vitro ( Fig. 4I ) and tumor growth in vivo ( Supplementary Fig. 6D ).
VEGF/NRP2 signaling regulates Bmi-1, which represses IGF-1R transcription
To establish the mechanism by which NRP2 represses the IGF-1R, we focused on our novel finding that NRP2 is required to maintain expression of Bmi-1, a Polycomb group ) ( Fig. 5D ).
Given that Bmi-1 is a transcriptional repressor and our finding that NRP2 represses expression of the IGF-1R, we examined the ability of Bmi-1 to repress IGF-1R transcription.
Initially, we observed that depletion of Bmi-1 expression in PC3 cells using shRNAs increased IGF-1R mRNA levels (Fig. 5E ). Loss of Bmi-1 also increased expression of the IGF-1R protein significantly confirming the importance of Bmi-1 in repressing IGF-1R expression (Fig. 5F ). To investigate the regulation of IGF-1R by Bmi-1, we performed ChIP using a Bmi-1 Ab and discovered that Bmi-1 binds directly to the IGF-1R promoter (Fig. 5G ). More specifically, Bmi-1 appears to bind to a region between -74 and -756 in the promoter (Fig. 5G ). As further proof that NRP2 represses IGF-1R expression by a Bmi-1-dependent mechanism, we infected PC3 cells that had been depleted of NRP2 with a lentivirus expressing Bmi-1 and assessed IGF-1R expression. We observed that Bmi-1 represses IGF-1R expression in the absence of NRP2 (Fig. 5H) .
Recently, we reported that VEGF/NRP2 signaling activates focal adhesion kinase (FAK) in concert with the α6β1 integrin (35, 36), and we observed that NRP2 and α6β1 interact in prostate carcinoma cells ( Supplementary Fig. 6E ). To investigate whether NRP2 mediated Bmi-1 expression involves FAK signaling, we evaluated FAK activation in tumor samples in vivo.
Tumor xenografts from NRP2-depleted cells show reduced FAK activation ( (Fig. 6B ). In addition, we also assessed FAK activation in tumor samples by immunostaining. We found that NRP2-high (PTEN-low) tumors express high levels of activated FAK (also localized to membrane) compared to NRP2-low (PTEN positive) tumors (Fig. 6C) . These data were confirmed by overexpression of constitutively active FAK (K38A) in NRP2-depleted cells, which resulted in increased expression of Bmi-1 (Fig. 6D) . To analyze the effect of c-Jun expression on FAK activation, we used LNCaP cells expressing low levels of NRP2 and observed that c-Jun expression increases NRP2, as well as FAK activation (Fig. 6E) . Similarly, downregulation of cJun reduced FAK activation and Bmi-1 expression; however, increased IGF-1R levels (Fig. 6F) .
A critical issue is whether the observed effects of NRP2 on Bmi-1 and IGF-1R expression involve VEGF, a NRP2 ligand. To address this issue, we down-regulated VEGF expression in PC3 cells using either siRNA or shRNA, and observed that decreased VEGF expression is associated with decreased Bmi-1 and increased IGF-1R expression (Fig. 7A-B , Supplementary Fig. 6F ). Moreover, exogenous VEGF increased Bmi-1 expression in a dosedependent manner ( Supplementary Fig. 6G ).
Our data also imply that VEGF expression should be higher in prostate tumors with PTEN loss compared with PTEN-positive tumors and that it should correlate with NRP2 and inversely with IGF-1R expression. To assess this hypothesis, qPCR was performed using RNA isolated from 12 prostate tumors (6 PTEN low and 6 PTEN high ). The PTEN low tumors exhibited relatively high expression of NRP2 and VEGF but low expression of the IGF-1R compared to the PTEN high tumors (Fig. 7C) . The expression pattern of VEGF is consistent with our finding that VEGF expression in tumor cells correlates with
Gleason grade (20). To exclude the possibility that VEGF regulation of Bmi-1 is mediated by other VEGF receptors, especially VEGF tyrosine kinase receptors, we used bevacizumab, which inhibits the interaction of VEGF with these receptors but not with NRP2 (22). A NRP2-blocking Ab inhibited VEGF induction of Bmi-1 expression but bevacizumab had no significant effect (Fig. 7D ).
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NRP2 is a biomarker that predicts response to IGF-1R therapy
Collectively, the data generated in this study indicate that NRP2 expression in tumor cells is a potential biomarker to predict the efficacy of IGF-1R inhibitors, which are currently in clinical trials. To test this latter possibility, we used two LuCaP xenograft models: and LuCaP-86.2. LuCaP-35 is sensitive to the IGF-1R inhibitor A12 and tumor growth is substantially inhibited upon A12 treatment. In contrast, LuCaP-86.2 is insensitive to A12 (Fig.   7E ). We detected significantly reduced expression of IGF-1R and increased expression of NRP2 and Bmi-1 in LuCaP-86.2 (PTEN-null) compared to LuCaP-35 (PTEN+) tumors.
Conversely, LuCaP-35 tumors expressed significantly higher levels of IGF-1R compared to NRP2 and Bmi-1 (Fig. 7F) .
These data were further strengthened by the analysis of an additional 15 A12-responders and 8 A12 non-responders (Fig. 7G, Supplementary Fig. 7 ). As shown in Fig. 7G , we detected 150-fold more NRP2 expression in the non-responders compared to responders and only a 10-fold increase in IGF-1R expression in the responders compared to the non-responders. To further substantiate our finding that NRP2 loss can enhance sensitivity to IGF-1R inhibition, we ablated NRP2 expression in LuCaP 86.2 cells and observed a significant increase in the response to A12 as assessed by cell proliferation (Fig.   7H ). Importantly, this response is associated with a significant decrease in Bmi-1 expression and increase in IGF-1R expression (Fig. 7H ).
DISCUSSION
Our data highlight a novel role for VEGF/NRP2 signaling in prostate cancer cells that impacts our understanding of the biological nature of this disease, especially aggressive prostate cancer, and our approach to therapy. Specifically, we conclude that the VEGF receptor NRP2 is induced by PTEN loss and that VEGF/NRP2 signaling regulates the expression of Bmi-1, a key effector of prostate tumorigenesis induced by PTEN deletion (16). The consequences of this mechanism are significant for several reasons, including our finding that Bmi-1 represses transcription of the IGF-1R and abrogates IGF-1R signaling. We exploited these results to demonstrate that NRP2 is a novel biomarker for high-grade prostate cancer that can be used to predict response to IGF-1R therapy. Importantly, our work indicates that combined NRP2 and IGF-1R inhibition is an effective approach for impeding tumor growth that overcomes the resistance caused by inhibiting either receptor independently.
A major conclusion from our work is that NRP2 expression and function are linked directly to oncogenic transformation associated with loss of PTEN function. More specifically, we show that PTEN loss induces NRP2 expression by activating JNK1/c-Jun and that an inverse correlation between PTEN and NRP2 expression is evident in both the PTEN pc-/-mice and in human prostate cancer. These expression data were substantiated by our finding that VEGF/NRP2 signaling regulates the expression of Bmi-1, a Polycomb group transcriptional repressor implicated in prostate tumorigenesis (16). Although a previous study had foreshadowed a role for NRP2 in the xenograft growth of colorectal carcinoma cells (37) DOI: 10.1158 /2159 ͳͶ Specifically, prostate carcinoma cells express VEGFR2 but lack expression of VEGFR1 ( Supplementary Fig. 2E ). The absence of VEGFR1 is consistent with previous reports and may result from hypermethylation of the VEGFR1 gene in prostate cancer (23, 24) . Nonetheless, the possibility that VEGFR2 contributes to NRP2 signaling is mitigated but not discounted by our finding that bevacizumab, which inhibits the interaction of VEGF with tyrosine kinase VEGF receptors but not with NRP2 (22), did not inhibit the ability of VEGF to regulate Bmi-1 Unexpectedly, we identified NRP2 as a novel c-Jun target that is regulated by PTEN.
The implication of these findings is that VEGF/NRP2 signaling is a component of the mechanism by which PTEN loss induces prostate cancer. Our key findings that VEGF/NRP2 signaling regulates Bmi-1 expression and that there is a strong correlation between NRP2 and Bmi-1 in human prostate cancer buttress this conclusion. The significance of these data is that they provide a causal link between VEGF/NRP2 signaling and a mechanism of prostate tumorigenesis, and they build upon the seminal report that Bmi-1 regulates the self-renewal of prostate stem cells and malignant transformation (16). Our data provide a specific mechanism (autocrine VEGF/NRP2 signaling) that contributes to Bmi-1 regulation in prostate cancer. Of note, this mechanism is consistent with the hypothesis that tumor stem cells secrete growth factors in an autocrine manner to protect themselves from differentiation and to support their self-renewal (38).
An important issue that arises from our data is how VEGF signals through NRP2 given that NRP2 lacks intrinsic signaling function. We hypothesize that the specific interaction between NRP2 and the α6β1 integrin (CD49f) potentiates this signaling. This hypothesis is based on our previous finding that NRP2 facilitates the α6β1-mediated activation of FAK and Src (36) and our observation here that NRP2 and α6β1 interact in prostate carcinoma cells.
Interestingly the association of NRP2 with α6β1 does not require the cytoplasmic domain of NRP2 ( Supplementary Fig. 6E ) indicating that this association occurs in the membrane, perhaps Author Manuscript Published OnlineFirst on July 9, 2012; DOI: 10.1158/2159-8290.CD-12-0085 ͳͷ in microdomains enriched for these receptors. We stress that our findings do not discount a role for tyrosine kinase VEGF receptors in promoting NRP2 signaling. Numerous studies have shown that the NRPs can enhance the function of these receptors (6, 7). It is important to note, however, that even if such VEGF receptors contribute to the signaling pathway we describe, NRP2 is essential and a prime target for therapeutic intervention.
Moreover, the data presented in Fig. 4J indicate that targeting NRP2 and IGF-1R is sufficient to block tumor growth in the absence of any other VEGF receptor inhibition.
We implicate FAK as a downstream effector of VEGF/NRP2 signaling that regulates Bmi-1 expression. This ability of FAK to regulate Bmi-1 is novel and it adds to our understanding of how FAK contributes to tumorigenesis. FAK expression is increased in prostate cancer cells compared to prostatic epithelium, and there is evidence that FAK participates in prostate tumorogenesis (39). FAK is also necessary for mammary tumorigenesis and for the function of mammary tumor stem cells (40) but the mechanism by which FAK functions in this capacity has not been elucidated. Clearly, the ability of FAK to regulate Bmi-1 provides one such mechanism. As mentioned above, it is likely that the α6β1 integrin is a component of this mechanism (35, 36).
Our data support the conclusion that IGF-1R expression and signaling are diminished in high-grade, aggressive prostate cancer, most likely as a result of PTEN loss. Although this conclusion is unexpected because IGF-1R signaling is thought to promote tumor proliferation in that are resistant to IGF-1R inhibition and will cause relapse unless this VEGF receptor is also targeted. NRP2 inhibition could be a very effective therapy for aggressive, high-grade tumors provided that the IGF-1R is also inhibited to reduce tumor burden caused by compensatory signaling. In summary, this study identifies NRP2 as a novel biomarker for predicting response to IGF-1R therapy. A critical finding in this context is that NRP2 is a much more robust biomarker than the IGF-1R itself. This finding is significant because the IGF-1R, is also expressed normal glands, in contrast to NRP2. Importantly, the data presented provide a rationale for initiating clinical trials that combine inhibitors of both NRP2 and IGF-1R.
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on were generated, titrated according to the manufacturer's instructions and used to infect cells following standard protocols. Stable cell transfectants were generated by puromycin selection (2 mg/ml). In some experiments, cells were transfected with VEGF siRNA (Smartpool, Dharmacon, Lafayette, CO, USA) or scrambled control siRNA.
Anchorage-independent growth assays Growth in soft agar was assayed by scoring the number of colonies formed in medium (DMEM supplemented with 10% FBS) containing 0.3% agarose, with a 0.5% agarose medium underlay as described (46). PC3-parental, PC3-GFP-sh or PC3-NRP2-sh (NRP2-sh-1 or NRP2-sh-2) cells were seeded on 60-mm diameter plates in triplicate. Cells were fed with 1.5 mL of suspension medium (DMEM supplemented with 10% FBS) every 3 days. The number of colonies larger than 100 ȝm was counted after 14 days.
Pten pc-/-mice
The Pten pc-/-mice (26), backcrossed more than 10 times to obtain a Balb/c
Research. DOI: 10.1158 /2159 ͳͻ background. Specimens of PIN (6 wks) or invasive prostate tumors (20 wks) from these mice and mice with wild-type PTEN were stained for NRP2 or NRP1 expression using IHC.
Luciferase assays Cells were transfected with the luciferase construct and Renilla luciferase construct to normalize for transfection efficiency. Relative light units were calculated as the ratio of firefly luciferase to Renilla luciferase activity (normalized luciferase activity). The protocol used for transfection and measurement of luciferase activity has been described previously (20).
We used a NRP2 promoter luciferase construct (-3000/+195) or the same construct with AP1 mutations. A full-length wild-type c-jun promoter (í1780/+731) luciferase construct was provided by Dr. Wayne Vedeckis (LSU Health Sciences Center) and used to study the effect of PTEN expression.
ChIP assays ChIP assays were performed according to our published protocol (47). All ChIP experiments were performed at least thrice and the variation was less than 20%. The primers used to amplify the IGF-1R and NRP2 promoters, as well as other genes analyzed in this study, are provided in Supplementary Fig. 8 . was amplified by PCR using primers specific for NP regions 1 to 7 (left gel) and the results were quantified by qPCR (right graph). The RT1-4 primers used for qPCR described in Figure S8 . 
Xenografts
